The U.S. Food and Drug Administration (FDA) is convening meetings this week to evaluate seven popular peptide substances that have gained significant traction for their purported benefits in weight loss, healing, and longevity. The FDA’s Pharmacy Compounding Advisory Committee is set to consider whether these peptides should be added to the agency’s 503A Bulks List, which would permit their use in certain compounded prescription drugs.

These peptides are currently available through various channels, including wellness clinics, compounding pharmacies, and online vendors, despite not holding FDA approval. Consumer demand for these substances is reportedly strong and is expected to persist regardless of the FDA's decision, driven by their use for weight loss, muscle building, performance enhancement, chronic disease management, and wound repair.

Peptides Under Review

The seven peptides under consideration by the FDA and their proposed uses include:

  • BPC-157: Proposed for ulcerative colitis, available in oral capsules, nasal spray, injections, transdermal cream, and rectal suppository forms.
  • TB-500: Suggested for wound healing, administered via subcutaneous or intramuscular injection.
  • KPV: Intended for wound healing and inflammatory conditions, available as a cream and gel.
  • MOTS-c: Proposed for obesity and osteoporosis, administered via subcutaneous injection.
  • Semax: Targeted for cerebral ischemia, migraines, and trigeminal neuralgia, available as an intranasal spray or subcutaneous injection.
  • Emideltide: Considered for opioid withdrawal, chronic insomnia, and narcolepsy, administered via subcutaneous injection.
  • Epitalon: Proposed for insomnia, administered via subcutaneous injection.

Expert Perspectives and FDA Concerns

Dr. Alex Tatem, a urologist and peptide expert who will testify at the hearings, argues that these substances have a promising safety profile based on years of patient use. He highlighted BPC-157 and TB-500 as compounds that can aid healing after injury and noted that millions of doses of BPC-157 have been administered with a low reported adverse event rate. Tatem attributes this safety to the peptides being natural substances familiar to the body.

However, FDA reviewers have expressed concerns regarding the limited evidence from human clinical trials to support the safety and efficacy of these seven substances. The agency cautions that a peptide's similarity to naturally occurring compounds does not preclude potential risks. Dr. Marc Siegel, a medical analyst, echoed these concerns, emphasizing the need for careful study and rigorous clinical trials, stating, "I am not convinced the data is fully there yet."

Robert F. Kennedy Jr., Secretary of Health and Human Services, has indicated support for expanding access to certain peptide therapies. He has also reportedly told Dr. Siegel that while some peptides may be helpful, others require further study, a sentiment Dr. Siegel agrees with, particularly concerning potential impacts on the kidneys.

Next Steps in the Review Process

Tatem anticipates a challenging review process but hopes the committee will consider real-world data from millions of doses administered between 2014 and 2023, which he claims showed adverse event rates well below 0.1%. If the advisory committee recommends inclusion on the 503A Bulks List, the FDA must still complete its review and rulemaking procedures.

Tatem expressed a desire for patients to be able to obtain prescriptions for these peptides under monitored medical supervision by the end of the year. He encouraged individuals to contact their representatives to advocate for access to safe, regulated peptides manufactured in the United States. The FDA has not commented on potential interim enforcement categories for these substances. The agency has been contacted for comment, as has ibuprofen manufacturer Haleon.